You are here: Industry Insights > Market News > Covaxin prices slashed from Rs 600 to Rs 400 per dose for states

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Covaxin prices slashed from Rs 600 to Rs 400 per dose for states

expresspharmaApril 30, 2021

Tag: Covaxin , Bharat Biotech , Serum Institute of India

Favorites

Bharat Biotech has slashed the price of its COVID-19 vaccine Covaxin for state governments from ₹600 to ₹400 per dose, the company said in a statement. The price of Covaxin for private healthcare providers is ₹1,200 per dose.

Covaxin prices slashed from Rs 600 to Rs 400 per dose for states

The announcement came one day after the Serum Institute of India, reduced the price of Covishield from ₹400 to ₹300.

“Bharat Biotech is deeply concerned with the critical pandemic circumstances that India is facing at this time. Recognising the enormous challenges to the public health care system, we have made Covaxin available to state governments at a price of ₹ 400 per dose,” the company said in a statement.

Previous:Pfizer Acquires Amplyx Pharmaceuticals

Next:Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Covaxin prices slashed from Rs 600 to Rs 400 per dose for states | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Covaxin prices slashed from Rs 600 to Rs 400 per dose for states

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Covaxin prices slashed from Rs 600 to Rs 400 per dose for states

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>